NCCN 2023 Annual Conference

Previous Poster Home Next

Assessment of Physician Treatment Preferences for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
07:30am - 03:45pm EDT - April 1, 2023

$Assessment of Physician Treatment Preferences for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) icon$

https://jnccn.org/view/journal...

Author(s):

Betsy J. Lahue, MPH, CEO, Alkemi, LLC

Tags: Outcomes and Health Services Research

Display Label	Action
AC23P116 - Assessment of Physician Treatment Preferences for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	Download MP3
116-General Poster Sesson	Download Handout